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COMMENTARY ON VIEWPOINT "WHY DO SOME PATIENTS STOP BREATHING AFTER TAKING NARCOTICS? VENTILATORY CHEMOSENSITIVITY AS A PREDICTOR OF OPIOID-INDUCED RESPIRATORY DEPRESSION"
TO THE EDITOR: We read with interest the Viewpoint from Potter and Moon (5) proposing that low chemoreceptor sensitivity may be a major contributor to opioid-induced apnea. We appreciate the focus on clinical incidents but believe that this might reflect only the tip of a very large iceberg. The number of drug overdose deaths in the United States continues to rise, with recreational opioid use contributing substantially to this increase (2) . Especially intriguing is that 50% of incidents occur in low-risk patients, Ͻ60 yr old.
So, what could we be overlooking? Related to the authors' hypothesis of low chemoreceptor sensitivity, we propose premature birth as a risk factor. Large-scale survival of very premature infants is a historically recent phenomenon and coincides with widespread surfactant use, beginning ϳ25 years ago. We recently found low chemoreceptor sensitivity in young adults born prematurely (1), evidenced by a blunted response to isocapnic, isobaric hypoxia. Complimentary studies in rats and premature infants suggest that this is caused by perinatal hyperoxia exposure, which impairs development of immature chemoreceptors (3, 4) . Evaluating prematurity will be challenging. Many preterm-born adults appear clinically indistinguishable from term-born adults and birth status is typically lost from the medical record with the transition from pediatric to adult care primary care. However, given the large number of premature births (12% of live births), we hope our colleagues will deem it worthy to evaluate this in subsequent endeavors.
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COMMENTARY ON VIEWPOINT "WHY DO SOME PATIENTS STOP BREATHING AFTER TAKING NARCOTICS? VENTILATORY CHEMOSENSITIVITY AS A PREDICTOR OF OPIOID-INDUCED RESPIRATORY DEPRESSION"
The commentary by Potter and Moon (4) is timely as excessive sedation results in opioid-induced respiratory depression (OIRD) and death (2) . The real dilemma is how to control pain and avoid respiratory depression in an individual patient? The opioids that bind primarily to the -receptors have the strongest analgesic effect and the greatest potential for respi-ratory depression (RD) by blunting the chemoreceptor response (1) . A test that predicts ahead of time patients at risk for RD, could improve perioperative management and the potential of saving lives. The authors propose that a system to measure noninvasively the ventilatory effects of a CO 2 challenge using respiratory inductance plethysmography (RIP) before and after a short-acting opioid (3) may identify patients at risk for OIRD. Ventilatory responses are variable even in healthy subjects (5) let alone in patients with significant pathology and are affected by numerous factors including metabolic activity. Although, RIP was validated in a small study of healthy subjects, this needs further review, particularly in patients with obesity and sleep disorders, who are prone to OIRD. The test could help in identifying a subgroup of patients in decreasing OIRD. However, screening tests are not perfect, as patient factors and sensitivity to opioid, pharmacokinetics, and drug interactions may still place patients at risk for OIRD. Nonetheless, predictors such as the one proposed by the authors need to be studied further to increase the awareness for opioid safety and individualized plans to decrease mortality from OIRD.
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COMMENT ON POTTER AND MOON'S VIEWPOINT: "WHY DO SOME PATIENTS STOP BREATHING AFTER TAKING NARCOTICS? VENTILATORY CHEMOSENSITIVITY AS A PREDICTOR OF OPIOID-INDUCED RESPIRATORY DEPRESSION"
TO THE EDITOR: Potter and Moon (4) discuss whether a decreased baseline ventilatory chemosensitivity might be a risk factor for opioid-induced respiratory depression (OIRD), a serious and potentially life-threatening complication associated with opioid treatment or abuse. If the association between chemoreceptor responsiveness and the occurrence of OIRD is robust, as suggested by the authors, then the routine assessment of "chemosensitivity" should be introduced into clinical guidelines. Potter and Moon's article emphasizes the use of the hypercapnic ventilatory response, probably on the basis that it serves to test both central and peripheral chemoreceptor activity. However, in my view, the assessment of peripheral responsiveness to hypoxia, which almost exclusively depends on carotid body (CB) function, is advisable for the following reasons. 1) Opioids and their receptors are expressed in the CB and are known to depress chemosensitivity during hypoxia (2) . Opioids appear to be coreleased with dopamine and have both auto/paracrine inhibitory effects on Ca 2ϩ currents in the CB and other peripheral neural tissues (1, 5) . The detection of hyporesponsive patients may therefore serve to alert to the danger of opioid treatment and, in particular, its association with drugs (e.g., Ca 2ϩ antagonists) that interfere with neurosecretion. 2) The CB is a highly plastic organ, with a neurogenic center (3) that is in direct contact with arterial blood and thus susceptible to damage by metabolic disturbances or modifications induced by morbidities such as hypertension, heart failure, or sleep apnea. Hence, changes in CB responsiveness to hypoxia may faithfully reflect clinically relevant individual variations (constitutive or acquired) of respiratory chemosensitivity among human populations.
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FURTHER CONSIDERATION OF VENTILATORY CHEMOSENSITIVITY AND OPIOID-INDUCED RESPIRATORY DEPRESSION
TO THE EDITOR: The high proportion of death caused by opioidinduced respiratory depression (OIRD) is primarily attributed to the lack of reliable predictors (5). Potter and Moon (5) proposed that the decrease in ventilator chemosensitivity may be a risk factor for OIRD. The alteration of chemosensitivity during opioid application is reflected by hypercapnic ventilatory response (HCVR), which can be associated with baseline HCVR (1), as a useful indicator for OIRD (5) .
We agree that chemosensitivity likely correlates to OIRD susceptibility with respect to individuals but some reservations could remain when this statement is applied across a population. As the authors mentioned, HCVR baseline can vary 80-fold among 211 healthy people (5) . Thus it is reasonable to speculate that the tolerance of chemosensitivity decline involved in OIRD can also change significantly from individual to individual. For example, the patients with obesity or chronic airflow obstruction are subject to a low chemosensitivity but can still demonstrate normal breathing. Their respiratory be-havior is believed to be further regulated by respiratory control system (2) .
In our view, the decrease of OIRD occurrence also depends on the identification of high-risk patients via reliable testing methods. For example, esophageal diaphragm electromyogram (EMGdi) can effectively assess neural respiratory drive (3) and distinguish between central and obstructive sleep apnea (4) . Future studies should emphasize the necessity on the correlation between chemosensitivity and OIRD susceptibility as well as related potential mechanisms.
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COMMENTARY ON VIEWPOINT "WHY DO SOME PATIENTS STOP BREATHING AFTER TAKING NARCOTICS? VENTILATORY CHEMOSENSITIVITY AS A PREDICTOR OF OPIOID-INDUCED RESPIRATORY DEPRESSION"
TO THE EDITOR: We connect this question and the article by Potter and Moon (3) to the increasingly prevalent epidemics of obesity, metabolic syndrome, and type 2 diabetes. A common feature of advanced type 2 diabetes, associated with extremes of HbA1c and elevated fasting glucose levels, is neuropathy (1) . Loss of sensation, particularly in limbs is common. O'Donnell et al. (2) showed that type 2 diabetes and its neuropathy may extend to the respiratory tract. They report diminished perception of inspiratory resistance in diabetics. It has also been reported that patients with type 2 diabetes exhibit diminished ventilatory responses to isocapnic hypoxia (4).
We have no data but raise the possibility of whether persons addicted to narcotics are more susceptible to overdose-induced respiratory depression when they have type 2 diabetes. A related question is the potential for increased risk of opioidinduced respiratory depression in persons with type 2 diabetes during surgery. Is neuropathy caused by type 2 diabetes associated with a greater respiratory depression when narcotic analgesics are used for preanesthetic medication, as supplements to other anesthetic agents, or as primary anesthetics?
Existing data should be gathered and analyzed to help answer these intriguing questions. Patient safety and public health may benefit from targeted research to elucidate the risks of opioid-induced respiratory depression in these vulnerable populations
